Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARPE DIEM: Rapamune in MCI and Early Alzheimer's
NCT04200911Phase 1Completed
- Sponsor
- UT Health San Antonio
- Start
- Jun 2020
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sirolimus in Alzheimer's disease (AD) and Mild Cognitive Impairment (MCI), sponsored by UT Health San Antonio. Primary endpoint: Blood Brain Barrier Penetration of RAPA at 8 weeks. Started Jun 2020; status: completed.
02
Drugs
sirolimus
03
Conditions
Alzheimer's disease (AD)Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT04200911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04200911.